T1	Intervention 291 347	patients with breast cancer, prostate cancer and myeloma
T2	Intervention 603 679	patients with bone metastases from tumors poorly responsive to chemotherapy,
T3	Intervention 784 985	Sixty-six patients with poorly responsive tumors such as non-small cell lung cancer (NSCLC), bladder cancer, gastrointestinal cancers, kidney cancer, melanoma and metastatic carcinoma of unknown origin
T4	Intervention 1294 1481	Of the 66 patients enrolled, 9 were observed for one month or less; 7 were followed for two months; only 50 patients were followed for more than 2 months and could be adequately evaluated
